EP2673635A4 - Immunothérapie par l'intermédiaire d'apoe - Google Patents
Immunothérapie par l'intermédiaire d'apoeInfo
- Publication number
- EP2673635A4 EP2673635A4 EP12744291.1A EP12744291A EP2673635A4 EP 2673635 A4 EP2673635 A4 EP 2673635A4 EP 12744291 A EP12744291 A EP 12744291A EP 2673635 A4 EP2673635 A4 EP 2673635A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- apoe
- immunotherapy
- apoe immunotherapy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 101150037123 APOE gene Proteins 0.000 title 1
- 101100216294 Danio rerio apoeb gene Proteins 0.000 title 1
- 238000009169 immunotherapy Methods 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/775—Apolipopeptides
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/775—Apolipopeptides
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2814—Dementia; Cognitive disorders
- G01N2800/2821—Alzheimer
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161440284P | 2011-02-07 | 2011-02-07 | |
PCT/US2012/024195 WO2012109280A2 (fr) | 2011-02-07 | 2012-02-07 | Immunothérapie par l'intermédiaire d'apoe |
Publications (2)
Publication Number | Publication Date |
---|---|
EP2673635A2 EP2673635A2 (fr) | 2013-12-18 |
EP2673635A4 true EP2673635A4 (fr) | 2015-08-12 |
Family
ID=46601594
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP12744291.1A Withdrawn EP2673635A4 (fr) | 2011-02-07 | 2012-02-07 | Immunothérapie par l'intermédiaire d'apoe |
Country Status (5)
Country | Link |
---|---|
US (3) | US20140050733A1 (fr) |
EP (1) | EP2673635A4 (fr) |
JP (1) | JP2014511174A (fr) |
CA (1) | CA2825791A1 (fr) |
WO (1) | WO2012109280A2 (fr) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104334184B (zh) | 2011-10-28 | 2017-12-29 | 普罗典娜生物科学有限公司 | 识别α‑突触核蛋白的人源化抗体 |
AU2013211874B2 (en) | 2012-01-27 | 2017-11-02 | Prothena Biosciences Limited | Humanized antibodies that recognize alpha-synuclein |
UA118441C2 (uk) * | 2012-10-08 | 2019-01-25 | Протена Біосаєнсиз Лімітед | Антитіло, що розпізнає альфа-синуклеїн |
MX2015012225A (es) | 2013-03-13 | 2016-01-08 | Prothena Biosciences Ltd | Inmunoterapia tau. |
US10513555B2 (en) | 2013-07-04 | 2019-12-24 | Prothena Biosciences Limited | Antibody formulations and methods |
CA2944402A1 (fr) | 2014-04-08 | 2015-10-15 | Prothena Biosciences Limited | Navettes de la barriere hemato-encephalique contenant des anticorps reconnaissant l'alpha-synucleine |
WO2017191561A1 (fr) | 2016-05-02 | 2017-11-09 | Prothena Biosciences Limited | Anticorps reconnaissant la protéine tau |
SG11201808434WA (en) | 2016-05-02 | 2018-10-30 | Prothena Biosciences Ltd | Antibodies recognizing tau |
PL3452507T3 (pl) | 2016-05-02 | 2023-01-09 | Prothena Biosciences Limited | Immunoterapia tau |
AU2017350947B2 (en) * | 2016-10-28 | 2024-02-15 | Washington University | Anti-ApoE antibodies |
MX2019013045A (es) | 2017-05-02 | 2020-02-12 | Prothena Biosciences Ltd | Anticuerpos que reconocen tau. |
SG11202108414UA (en) | 2019-03-03 | 2021-08-30 | Prothena Biosciences Ltd | Antibodies recognizing tau |
JP2023502515A (ja) | 2019-11-25 | 2023-01-24 | コーネル・ユニバーシティー | Apoe遺伝子療法 |
CN112538113B (zh) * | 2020-08-06 | 2023-07-21 | 武汉天德生物科技有限公司 | 杂交瘤细胞株ace8及其产生的apoe4点突变单克隆抗体 |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040157267A1 (en) * | 2002-07-30 | 2004-08-12 | Yadong Huang | Method of diagnosing Alzheimer's Disease |
US20070104715A1 (en) * | 2003-11-28 | 2007-05-10 | Astrazeneca Ab | Antibodies binding to a c-terminal fragment of apoliopoprotein e |
WO2008076487A2 (fr) * | 2006-12-20 | 2008-06-26 | Verenium Corporation | Anticorps: procédé de fabrication et d'utilisation |
WO2008089070A2 (fr) * | 2007-01-12 | 2008-07-24 | Dyax Corp. | Polythérapie pour le traitement du cancer |
WO2010033736A1 (fr) * | 2008-09-17 | 2010-03-25 | Xencor, Inc. | Nouvelles compositions et nouvelles méthodes de traitement d'affections médiées par les ige |
EP2194066A1 (fr) * | 2007-09-26 | 2010-06-09 | Chugai Seiyaku Kabushiki Kaisha | Région constante d'anticorps modifié |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030032159A1 (en) | 2001-01-30 | 2003-02-13 | Yizhong Gu | Human ralgds-like protein 3 |
US7365167B2 (en) * | 2001-11-26 | 2008-04-29 | Cell Matrix, Inc. | Humanized collagen antibodies and related methods |
US7241444B2 (en) | 2002-01-18 | 2007-07-10 | Pierre Fabre Medicament | Anti-IGF-IR antibodies and uses thereof |
US20050281828A1 (en) * | 2003-03-04 | 2005-12-22 | Bowdish Katherine S | Method of treating autoimmune disease by inducing antigen presentation by tolerance inducing antigen presenting cells |
US20060075522A1 (en) | 2004-07-31 | 2006-04-06 | Jaclyn Cleveland | Genes and uses for plant improvement |
CN104558200B (zh) * | 2004-09-02 | 2021-11-16 | 康石医药科技(上海)有限公司 | 改进的apo e类似物及其使用方法 |
CA2589860A1 (fr) * | 2005-01-24 | 2006-08-03 | Amgen Inc. | Anticorps anti-amyloide humanise |
WO2007075318A2 (fr) | 2005-12-07 | 2007-07-05 | The J. David Gladstone Institutes | Agents qui reduisent la degradation induite par apoe des mitochondries, et leurs procedes d'utilisation |
CA2653628C (fr) | 2006-06-01 | 2015-07-14 | Elan Pharmaceuticals, Inc. | Fragments neuroactifs de app |
US20090022728A1 (en) | 2007-03-09 | 2009-01-22 | Rinat Neuroscience Corporation | Methods of treating ophthalmic diseases |
AU2008320987B2 (en) | 2007-11-13 | 2014-04-17 | Teva Biopharmaceuticals Usa, Inc. | Humanized antibodies against TL1A |
FI20085579A0 (fi) | 2008-06-12 | 2008-06-12 | Valtion Teknillinen | Kannabiskäytön toteaminen |
US8466260B2 (en) * | 2009-04-01 | 2013-06-18 | Genentech, Inc. | Anti-FcRH5 antibodies and immunoconjugates and methods of use |
-
2012
- 2012-02-07 US US13/984,215 patent/US20140050733A1/en not_active Abandoned
- 2012-02-07 US US13/368,260 patent/US8741298B2/en not_active Expired - Fee Related
- 2012-02-07 JP JP2013552736A patent/JP2014511174A/ja active Pending
- 2012-02-07 WO PCT/US2012/024195 patent/WO2012109280A2/fr active Application Filing
- 2012-02-07 CA CA2825791A patent/CA2825791A1/fr not_active Abandoned
- 2012-02-07 EP EP12744291.1A patent/EP2673635A4/fr not_active Withdrawn
-
2014
- 2014-05-28 US US14/289,546 patent/US20140348843A1/en not_active Abandoned
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040157267A1 (en) * | 2002-07-30 | 2004-08-12 | Yadong Huang | Method of diagnosing Alzheimer's Disease |
US20070104715A1 (en) * | 2003-11-28 | 2007-05-10 | Astrazeneca Ab | Antibodies binding to a c-terminal fragment of apoliopoprotein e |
WO2008076487A2 (fr) * | 2006-12-20 | 2008-06-26 | Verenium Corporation | Anticorps: procédé de fabrication et d'utilisation |
WO2008089070A2 (fr) * | 2007-01-12 | 2008-07-24 | Dyax Corp. | Polythérapie pour le traitement du cancer |
EP2194066A1 (fr) * | 2007-09-26 | 2010-06-09 | Chugai Seiyaku Kabushiki Kaisha | Région constante d'anticorps modifié |
WO2010033736A1 (fr) * | 2008-09-17 | 2010-03-25 | Xencor, Inc. | Nouvelles compositions et nouvelles méthodes de traitement d'affections médiées par les ige |
Non-Patent Citations (3)
Title |
---|
HUANG Y ET AL: "Apolipoprotein E fragments present in Alzheimer's disease brains induce neurofibrillary tangle-like intracellular inclusions in neurons", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, NATIONAL ACADEMY OF SCIENCES, US, vol. 98, no. 15, 1 January 2001 (2001-01-01), pages 8838 - 8843, XP002954822, ISSN: 0027-8424, DOI: 10.1073/PNAS.151254698 * |
KARL H WEISGRABERSS ET AL: "Human apolipoprotein E. Determination of the heparin binding sites of apolipoprotein E3", THE JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 261, no. 7, 15 February 1986 (1986-02-15), pages 2068 - 2076, XP055198377 * |
YAMADA T ET AL: "Further characterization of a monoclonal antibody recognizing apolipoprotein E peptides in amyloid deposits", ANNALS OF CLINICAL AND LABORATORY SCIENCE, INSTITUTE FOR CLINICAL SCIENCE, PHILADELPHIA, PA, US, vol. 27, no. 4, 1 July 1997 (1997-07-01), pages 276 - 281, XP002978336, ISSN: 0091-7370 * |
Also Published As
Publication number | Publication date |
---|---|
US20140050733A1 (en) | 2014-02-20 |
US8741298B2 (en) | 2014-06-03 |
US20140348843A1 (en) | 2014-11-27 |
EP2673635A2 (fr) | 2013-12-18 |
WO2012109280A3 (fr) | 2013-11-14 |
WO2012109280A2 (fr) | 2012-08-16 |
US20120204275A1 (en) | 2012-08-09 |
CA2825791A1 (fr) | 2012-08-16 |
JP2014511174A (ja) | 2014-05-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK3424953T3 (en) | Terapeutiske antistoffer | |
EP2755962A4 (fr) | Azaindazoles | |
EP2715659A4 (fr) | Überfeed | |
EP2771126A4 (fr) | Dispositif de fusion | |
EP2673635A4 (fr) | Immunothérapie par l'intermédiaire d'apoe | |
EP2754063A4 (fr) | Extensibilité du protocole smb2 | |
EP2723631A4 (fr) | Catamaran à quatre ailes portantes | |
AP2014007621A0 (en) | 2-Thiopyrimidinones | |
ZA201403050B (en) | R(+)-n-methyl-propargyl-aminoindan | |
ZA201403043B (en) | R(+)-n-formyl-propargyl-aminoindan | |
HUE052855T2 (hu) | Kolonoszkópiás készítmény | |
EP2695208A4 (fr) | Micro-thermocouple | |
HK1202794A1 (zh) | 丙型肝炎病毒的免疫治療 | |
EP2679138A4 (fr) | Endoscope | |
GB201301300D0 (en) | No details | |
EP2708561A4 (fr) | Bio-aiguille | |
GB201119167D0 (en) | Novel bachteriophages | |
DK2770906T3 (en) | Applanationstonometer | |
EP2684382A4 (fr) | Capuchon d'écouteur | |
EP2698098A4 (fr) | Campimètre | |
EP2694655A4 (fr) | pAVEC | |
EP2702929A4 (fr) | Campimètre | |
GB201100001D0 (en) | TidySqueeze2 | |
AU4540P (en) | BUNNAN Baloskion tetraphyllum | |
AU5171P (en) | Sunparamiho Mandevilla xamabilis |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20130909 |
|
AK | Designated contracting states |
Kind code of ref document: A2 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: NEOTOPE BIOSCIENCES LIMITED |
|
REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1192617 Country of ref document: HK |
|
DAX | Request for extension of the european patent (deleted) | ||
A4 | Supplementary search report drawn up and despatched |
Effective date: 20150710 |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: C07K 16/18 20060101ALI20150706BHEP Ipc: C12N 5/10 20060101ALI20150706BHEP Ipc: G01N 33/48 20060101AFI20150706BHEP Ipc: C12N 1/19 20060101ALI20150706BHEP Ipc: C07K 17/00 20060101ALI20150706BHEP Ipc: A61K 39/385 20060101ALI20150706BHEP Ipc: A61P 25/28 20060101ALI20150706BHEP Ipc: A61P 25/00 20060101ALI20150706BHEP Ipc: A61K 39/00 20060101ALI20150706BHEP Ipc: C07K 4/12 20060101ALI20150706BHEP Ipc: A61K 39/395 20060101ALI20150706BHEP Ipc: C07H 21/04 20060101ALI20150706BHEP Ipc: C12N 1/21 20060101ALI20150706BHEP |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20160209 |
|
REG | Reference to a national code |
Ref country code: HK Ref legal event code: WD Ref document number: 1192617 Country of ref document: HK |